Contact

Ross McNaughton

Partner

Read More
Contact

Ross McNaughton

Partner

Read More

30 September 2022

Supporting regional talent growth with our new Cambridge training contracts

We have reaffirmed our commitment to the Cambridge region by offering two new training contracts in our office, beginning as early as next year.

As part of our strategic growth plans, the firm will be recruiting for the next generation of Cambridge-based legal talent to start their training contract in either 2023 or 2024, recruited through the firm's summer vacation scheme. We already recruit 20-24 trainees into our London office each year; applicants are recruited through the vacation scheme or internal process.

The firm's well-established Cambridge office is one of the leading practices in the region for life sciences, patents, and corporate work. The office is ranked in the top tier across multiple practice areas by leading independent legal directory The Legal 500.

The office boasts an impressive client base ranging from start-ups to life sciences and tech companies on a high-growth trajectory, most recently advising protein printing start-up Nuclera on its $58 million Series B funding round.

Ross McNaughton, partner in our Corporate Technology and Life Sciences team and head of the Cambridge office, said: "Nurturing our home-grown junior talent in the Cambridge office has been a long-term goal for us as a firm, which is why it's so rewarding to see this plan come to fruition.

"Our Cambridge office has a hugely exciting remit covering some of the cutting-edge technology being developed in the region and beyond, so offering training contracts here is an incredible opportunity for those looking to carve out a legal career in tech or life sciences.

"We're looking forward to finding the right fit for our successful teams in these practice areas and kickstarting two promising legal careers in the Cambridge region."

Applications open on 1 October for the summer vacation scheme via our Early Talent webpage.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Corporate/M&A & capital markets

Advising Baseimmune on its £9 million funding round

22 March 2024

by Ross McNaughton and Oli Denne

Click here to find out more
Corporate/M&A & capital markets

Advising on Mission Zero Technologies on its £21.8 million Series A funding

20 March 2024

by Ross McNaughton and Oli Denne

Click here to find out more
Life sciences & healthcare

Advising gene therapy company AlveoGene on its complex spinout and launch investment

23 October 2023

by multiple authors

Click here to find out more